Meta-analysis: Insulin sensitizers for the treatment of non-alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 10, 2010, Pages 1211-1221

  Rakoski, M O ^a   Singal, A G ^a   Rogers, M A M ^b   Conjeevaram, H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; META ANALYSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 78249262957     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04467.x     Document Type: Article

References (44)

1. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132: 112-7.
2. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105: 1567-73.
3. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ,. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262-5.
4. Haynes P, Liangpunsakul S, Chalasani N,. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis 2004; 8: 535-47.
5. Ekstedt M, Franzãn LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
6. Ong JP, Pitts A, Younossi ZM,. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
7. Edens MA, Kuipers F, Stolk RP,. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obesity reviews 2009; 10: 412-9.
8. Picardi A, Vespasiani-Gentilucci U,. Association between non-alcoholic fatty lvier disease and cardiovascular disease: a first message should pass. Am J Gastroenterol 2008; 103: 3036-8.
9. Bellentani S, Marino M,. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (Suppl 1): S4-8.
10. Ratziu V, Zelber-Sagi S,. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 667-88.
11. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (NASH). Hepatology 2010; 51: 121-9.
12. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072-81.
13. Cusi K,. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 545-63.
14. Gentile CL, Pagliassotti MJ,. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008; 19: 567-76.
15. Oh MK, Winn J, Poordad F,. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 503-22.
16. Tiniakos DG, Vos MB, Brunt EM,. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-71.
17. Shulman GI,. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-6.
18. Bray GA,. Medications for obesity: mechanisms and applications. Clin Chest Med 2009; 30: 525-38.
19. Higgins JPT, Green S, (editors). Cochrane handbook for systematic reviews of interventions version 5.0.2. The Cochrane Collaboration, 2009. Available at:.
20. Follmann D, Elliott P, Suh I, Cutler J,. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-73.
21. Cochran W,. The combination of estimated from different experiments. Biometrics 1954; 10: 101-29.
22. Higgins JPT, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Statist Med 2002; 21: 1539-58.
23. Copas J, Shi JQ,. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 2000; 1: 247-62.
24. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple graphical test. BMJ 1996; 315: 629-34.
25. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med 2010; 362: 1675-85.
26. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
27. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84.
28. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
29. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
30. Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 200-8.
31. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ,. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot study. Therap Adv Gastroenterol 2009; 2: 157-63.
32. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44.
33. Haukeland JW, Konopski Z, Eggesbã HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-60.
34. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL,. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
35. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH,. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121: 1868-77.
36. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-9.
37. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-53.
38. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
39. Durbin RJ,. Thiazolidinedione therapy in the preventin.delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-5.
40. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803.
41. Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-78.
42. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-35.
43. Garg R, Tripathy D, Dandona P,. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 2003; 4: 487-92.
44. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.